Palatin Technologies, Inc. (NYSE Amex: PTN) announced that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment...